The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks Start Mostly Lower Amid Profit Taking

Tue, 31st Dec 2019 08:51

(Alliance News) - London stocks were lower on Tuesday morning, with some traders remaining away from their desks ahead of the New Year's Day holiday, while others were cashing out of a flagging Santa Rally.

The FTSE 100 index was down 43.63 points, or 0.6%, at 7,543.42 early Tuesday. The mid-cap FTSE 250 index was 33.44 points lower, or 0.2%, at 21,902.82, and the AIM All-Share index was flat at 958.11.

The retreat follows a strong Christmas week for London shares, with the FTSE 250 index of mid-caps reaching a record closing high, breaching the 22,000 mark for the first time.

The Cboe UK 100 index was down 0.6% at 12,783.36. The Cboe 250 was 0.2% lower at 19,815.78, and the Cboe Small Companies flat at 12,247.11.

The London Stock Exchange will close early at 1230 GMT for New Year's Eve. It will re-open on Thursday for a full session.

Sterling was quoted at USD1.3130 early Tuesday, flat with USD1.3136 at the London equities close on Monday.

In other currencies, the euro was trading at USD1.1205 early Tuesday, soft on USD1.1216 late Monday. Against the yen, the dollar was at JPY108.63, down slightly from JPY108.83.

In mainland Europe, the CAC 40 in Paris was down 0.4%. Financial markets in France will close early on Tuesday, while German markets are completely closed for New Year's Eve. Italy and Switzerland also are closed all day.

In Asia on Tuesday, financial markets were closed in Japan. In China, the Shanghai Composite ended up 0.3%, while the Hang Seng index in Hong Kong closed down 0.5%.

Tokyo will remain shut until Monday, while the Shanghai and Hong Kong markets are closed on New Year's Day but reopen on Thursday.

Back in London, HSBC Holdings started the day 0.6% lower after the Financial Times reported that the bank is planning to expand its exchange traded fund range in 2020 in order to revitalise its underperforming asset management business.

Nicholas Moreau, who was appointed chief executive of HSBC's asset management division in August, has devised a series of initiatives aimed at reinvigorating growth at a time when the London-listed bank is aggressively cutting costs, the FT said.

In the first half of 2020, HSBC will launch eight ETF's employing environmental, social and governance metrics to tap into rising investor demand for ESG-focused strategies.

HSBC also plans to develop a fixed income ETF platform in 2020 and to launch a range of precious metals tracker funds later in the year, the FT noted.

On AIM, Redx Pharma surged 31% in early trade to 8.68 pence. The company reported it is in "active" discussions with Samuel Waksal and associates, which could lead to a possible cash offer for the company.

In the meantime, the drug discovery and development company called on its shareholders to vote in favour of the conversion of a GBP2.5 million loan into shares. A general meeting will be held on January 21.

"We believe that this short-term funding solution will allow us time to secure the necessary longer-term funding that will enable us to advance our innovative pipeline of novel precision medicines for cancer and fibrosis," explained Chair Iain Ross.

The loan agreement was signed back in June with Moulton Goodies Ltd, Redx's largest shareholder which has over 18% stake, for a fixed rate secured loan note facility of up to GBP2.5 million. The loan is repayable in full on Tuesday. However, Moulton has requested that Redx capitalise the whole of the loan, including all unpaid interest, into new shares.

The capitalisation price pursuant to the terms of the loan notes is 5.25p per share, which will result in the issue of 52.0 million new shares to Moulton.

In the red early Tuesday was KCR Residential REIT, down 9.3%, after saying that it has been unable to publish its results for the year to the end of June until the end of 2019. The company explained that it is in the process of finalising the audit and the results will be announced "as soon as possible".

The delay is procedural having been caused by time-delays during the course of the audit which started later than expected following the closing of the corporate transaction with Torchlight Fund, the company said.

KCR Residential REIT shares will be suspended on Thursday.

Gold was quoted at USD1,524.30 early Tuesday, up from USD1,515.03 at the London equities close on Monday.

Brent oil was trading at USD66.48 early Tuesday, firm on USD66.14 at the London equities close on Monday.

The economic events calendar on Tuesday has only US data. The Johnson Redbook retail sales index is at 1355 GMT, with the monthly house price index at 1400 GMT and the US consumer confidence index at 1500 GMT.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
24 Feb 2016 09:44

Redx Pharma Makes Progress On Gonorrhoea Treatment And Other Drugs

Read more
20 Jan 2016 10:00

Redx Pharma Continues Pipeline Progressing In Maiden Results

Read more
13 Jan 2016 16:00

Earnings, Trading Statements Calendar - Week Ahead

Read more
4 Jan 2016 08:35

New Redx director brings scientific, commercial expertise

(ShareCast News) - Redx announced the appointment of a non-executive director on Monday, with Dr Bernhard Kirschbaum joining the firm's board immediately. The AIM-listed self-described drug discovery and development company said Dr Kirschbaum was bringing with him more than 25 years experience in ph

Read more
3 Dec 2015 07:54

Redx Pharma Identifies New Cancer Drug Development Candidate

Read more
6 Nov 2015 09:42

DIRECTOR DEALINGS: Redx Pharma Chairman, Non-Executives Buy Shares

Read more
1 Oct 2015 07:36

Redx Pharma Says It Made "Good Progress" In Second Half

Read more
3 Sep 2015 08:00

Redx Pharma And Horizon Discovery Collaborating On Cancer Research

Read more
22 Jun 2015 14:17

Redx Pharma enjoys good progress during first-half

Two months after its admission to AIM, Redx Pharma said its first-half results were in line with expectations thanks to progress on potential MRSA drugs. Losses before tax rose 60.5% to £3.26m due to a decrease in grant funding and operating expenses increased 5% to £5.48m. The drug discovery and d

Read more
22 Jun 2015 08:35

Redx Pharma Positive For Full Year, Loss Widens In Maiden Interims

Read more
2 Jun 2015 11:13

Redx Pharma cheers with progress on potential MRSA drug

Redx shares jumped on the news it has reached the pre-clinical development stage with a new anti-infective compound designed to tackle MRSA, the bacteria that causes potentially lethal infections in humans. The pharmaceutical firm said the progress marked a "significant milestone" for its commercial

Read more
2 Jun 2015 07:00

Redx Pharma Progresses To Pre-Clinical Stage With MRSA Treatment

Read more
26 May 2015 07:43

Redx Pharma Identifies Second Drug Development Candidate

Read more
14 May 2015 09:41

Redx Pharma To Launch New Immunology Subsidiary

Read more
14 May 2015 08:55

Redx Pharma Says Third Paper On Antimicrobial Resistance Published

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.